Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO)
CUSIP: 869367102
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.001 par value
- Shares outstanding
- 84,733,230
- Total 13F shares
- 290,035
- Share change
- -53,031,271
- Total reported value
- $3,355,706
- Price per share
- $11.57
- Number of holders
- 6
- Value change
- -$73,977,683
- Number of buys
- 1
- Number of sells
- 81
Quarterly Holders Quick Answers
What is CUSIP 869367102?
CUSIP 869367102 identifies STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 869367102:
Top shareholders of STRO - Sutro Biopharma, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Affinity Asset Advisors, LLC |
13D/G
13F
|
Affinity Healthcare Fund, LP · Company |
7.8%
|
6,583,772
|
$5,717,348 | $0 | 16 Oct 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
7.7%
|
6,488,324
|
$5,634,461 | — | 30 Sep 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
|
Company |
5.6%
|
4,717,215
|
$4,434,182 | $0 | 27 Jun 2025 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
5,088,099
|
$4,418,505 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.9%
from 13D/G
|
3,682,986
|
$3,196,832 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
4%
|
3,389,322
|
$2,941,000 | — | 30 Sep 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
3.7%
|
3,120,000
|
$2,709,408 | — | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
3.3%
|
2,828,717
|
$2,456,458 | — | 30 Sep 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
3.2%
|
2,723,509
|
$2,365,095 | — | 30 Sep 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
3.1%
|
2,600,000
|
$2,257,840 | — | 30 Sep 2025 | |
| Eversept Partners, LP |
13F
|
Company |
2.7%
|
2,291,313
|
$1,989,776 | — | 30 Sep 2025 | |
| Samsara BioCapital, LLC |
13F
|
Company |
2.6%
|
2,196,814
|
$1,907,713 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
2.4%
|
2,000,000
|
$1,736,800 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
2.2%
|
1,845,839
|
$1,602,188 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
2.5%
|
2,092,281
|
$1,493,679 | -$2,892,242 | 30 Jun 2025 | |
| William J. Newell |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
768,806
mixed-class rows
|
$1,399,621 | — | 05 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
1.7%
|
1,424,797
|
$1,237,294 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.97%
|
820,948
|
$713,188 | — | 30 Sep 2025 | |
| Trevor Hallam |
3/4/5
|
Pres. Rsrch & Cf. Sctific Ofcr |
—
mixed-class rows
|
107,868
mixed-class rows
|
$507,563 | — | 14 Apr 2023 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.53%
|
445,750
|
$387,089 | — | 30 Sep 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.52%
|
437,079
|
$379,559 | — | 30 Sep 2025 | |
| Arturo Molina MD |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
127,236
mixed-class rows
|
$354,016 | — | 04 Mar 2022 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.47%
|
396,785
|
$344,568 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.42%
|
354,449
|
$307,804 | — | 30 Sep 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.42%
|
352,949
|
$306,500 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.4%
|
342,652
|
$297,559 | — | 30 Sep 2025 | |
| Shabbir Anik |
3/4/5
|
Chief Technical Ops. Officer |
—
mixed-class rows
|
58,327
mixed-class rows
|
$274,452 | — | 03 Mar 2023 | |
| Shay Capital LLC |
13F
|
Company |
0.37%
|
312,051
|
$270,985 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.31%
|
258,876
|
$225,000 | — | 30 Sep 2025 | |
| Venkatesh Srinivasan |
3/4/5
|
CHIEF TECH OP OFFICER |
—
mixed-class rows
|
254,436
mixed-class rows
|
$214,524 | — | 01 May 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.29%
|
241,885
|
$210,053 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.28%
|
239,400
|
$207,895 | — | 30 Sep 2025 | |
| Anne Elizabeth Borgman |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
115,264
mixed-class rows
|
$195,061 | — | 01 May 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.23%
|
197,516
|
$171,522 | — | 30 Sep 2025 | |
| AJU IB Investment Co., Ltd. |
13F
|
Company |
0.21%
|
175,000
|
$153,125 | — | 30 Sep 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.21%
|
174,843
|
$152,000 | — | 30 Sep 2025 | |
| Edward C. Albini |
3/4/5
|
CFO AND SECRETARY |
0.19%
|
160,805
|
$141,508 | — | 15 May 2025 | |
| Linda A. Fitzpatrick |
3/4/5
|
CHIEF PEOPLE & COMM. OFFICER |
—
mixed-class rows
|
136,658
mixed-class rows
|
$134,667 | — | 01 May 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.18%
|
152,714
|
$132,617 | — | 30 Sep 2025 | |
| Barbara Leyman |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
182,056
mixed-class rows
|
$127,443 | — | 08 Jul 2025 | |
| LPL Financial LLC |
13F
|
Company |
0.17%
|
142,883
|
$124,080 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.16%
|
134,919
|
$117,164 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.14%
|
122,115
|
$106,045 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.14%
|
119,434
|
$103,669 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.14%
|
118,443
|
$103,045 | — | 30 Sep 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.12%
|
103,592
|
$89,959 | — | 30 Sep 2025 | |
| OMERS ADMINISTRATION Corp |
13F
|
Company |
0.11%
|
95,150
|
$82,628 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.1%
|
88,111
|
$76,515 | — | 30 Sep 2025 | |
| Nicki Vasquez |
3/4/5
|
CHIEF PORT. STRAT & ALNCE OFCR |
—
class O/S missing
|
14,279
|
$71,252 | — | 29 Jan 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.09%
|
76,158
|
$66,135 | — | 30 Sep 2025 |
Institutional Holders of Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) as of Q4 2025
As of 31 Dec 2025,
Sutro Biopharma, Inc. - Common Stock, $0.001 par value (STRO) was held by
6 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
290,035 shares.
The largest 6 holders included
Merck & Co., Inc., AJU IB Investment Co., Ltd., Fortitude Family Office, LLC, Bogart Wealth, LLC, Parallel Advisors, LLC, and EverSource Wealth Advisors, LLC.
This page lists
6
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
84
Q4 2025 holders
6
Holder diff
-78
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.